Tumor News and Research

RSS

Researchers shed new light on how gliomas cells migrate in brain and cause devastating tumors

Researchers at the University of Alabama at Birmingham have shed new light on how cells called gliomas migrate in the brain and cause devastating tumors.

20 Jun 2014

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

20 Jun 2014

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

20 Jun 2014

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Only 15% of patients with squamous cell lung cancer - the second most common lung cancer - survive five years past diagnosis.

20 Jun 2014

New technique identifies tumors in real time in operating room

Before they excise a tumor, surgeons need to determine exactly where the cancerous cells lie. Now, research published today in The Optical Society's (OSA) journal Optics Letters details a new technique that could give surgeons cheaper and more lightweight tools, such as goggles or hand-held devices, to identify tumors in real time in the operating room.

20 Jun 2014

ChromaDex enters into joint collaboration agreement with St. Jude Children's Research Hospital

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.

19 Jun 2014

Researchers discover crucial process that regulates development of blood vessels

Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels.

19 Jun 2014

African American women with invasive breast cancer less likely to receive invasive technique

African American women with early stage, invasive breast cancer were 12 percent less likely than Caucasian women with the same diagnosis to receive a minimally invasive technique, axillary sentinel lymph node (SLN) biopsy, even as the procedure had become the standard of surgical practice, according to research from The University of Texas MD Anderson Cancer Center.

19 Jun 2014

Researchers develop device that spots lung cancer

Lung cancer causes more deaths in the U.S. than the next three most common cancers combined (colon, breast, and pancreatic).

19 Jun 2014

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA.

18 Jun 2014

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies.

18 Jun 2014

New strategy for treating neuroblastoma using modified version of heparin

Researchers at Duke Medicine have identified a new strategy for treating neuroblastoma using a modified version of heparin, a century-old injectable drug that thins the blood to prevent clots from forming.

18 Jun 2014

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Australian oncology drug development company Novogen Limited and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

18 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Western Oncolytics closes $275,000 in seed funding

Western Oncolytics Ltd., a biotech company specializing in immuno-oncolytic cancer therapies, has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells.

18 Jun 2014

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.

18 Jun 2014

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.

18 Jun 2014

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer Inc. and Cellectis today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.

18 Jun 2014

Researchers identify new mechanism by which normal cells turn malignant in mammary epithelial tissues

A team of researchers led by David J. Mooney, Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences, have identified a possible mechanism by which normal cells turn malignant in mammary epithelial tissues, the tissues frequently involved in breast cancer.

17 Jun 2014

Lipids efficiently kill leukemia cells

T cells use a novel mechanism to fight leukemia. They may recognize unique lipids produced by cancer cells and kill tumor cells expressing these lipid molecules.

17 Jun 2014

Tumor News and Research

Researchers shed new light on how gliomas cells migrate in brain and cause devastating tumors

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

New treatment for ovarian cancer can improve response rates

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

New technique identifies tumors in real time in operating room

ChromaDex enters into joint collaboration agreement with St. Jude Children's Research Hospital

Researchers discover crucial process that regulates development of blood vessels

African American women with invasive breast cancer less likely to receive invasive technique

Researchers develop device that spots lung cancer

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

New strategy for treating neuroblastoma using modified version of heparin

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Western Oncolytics closes $275,000 in seed funding

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Researchers identify new mechanism by which normal cells turn malignant in mammary epithelial tissues

Lipids efficiently kill leukemia cells

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News